# A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects

> **NCT07585383** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jiangxi Kvvit Pharmaceutical Co., Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** KR23248
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT07585383
- **Lead sponsor:** Jiangxi Kvvit Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-19
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07585383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07585383, "A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07585383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*